Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Minimal clinically important difference

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Minimal clinically important difference. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-004281-19 Sponsor Protocol Number: 1.5 Start Date*: 2022-06-08
    Sponsor Name:Region Stockholm Karolinska University Hospital (Dep. of Dermatology)
    Full Title: Investigator initiated clinical trial of dantrolene as a treatment for Darier disease
    Medical condition: Darier disease is a rare and severe autosomal dominant skin disorder.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001805-40 Sponsor Protocol Number: TRICORDA Start Date*: 2023-03-27
    Sponsor Name:Hospital Universitario Lucus Augusti
    Full Title: Increase in inhaled corticosteroid dose vs triple therapy in T2-high asthma patients who remain uncontrolled with medium dose inhaled corticosteroids/long-acting β2 adrenergic combination: a real-l...
    Medical condition: Asthma is an important global health problem that affects people of all ages . Despite effective and safe therapeutic options, up to 75% of patients with asthma remain uncontrolled . It remains to ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002511-34 Sponsor Protocol Number: V1.0.14062017 Start Date*: 2018-09-26
    Sponsor Name:Academisch Medisch Centrum
    Full Title: Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP (OPTIC trial)
    Medical condition: Chronic inflammatory demyelinating polyneuropathy (CIDP)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001241-13 Sponsor Protocol Number: CAIN457F2306E1 Start Date*: 2013-09-10
    Sponsor Name:Novartis Farma SpA
    Full Title: A three-year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active psoriatic arthritis
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PL (Completed) BG (Completed) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004101-75 Sponsor Protocol Number: S56122-ML10190 Start Date*: 2014-03-28
    Sponsor Name:UZ Leuven
    Full Title: Randomized crossover trial to assess the effects and quality of life in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel: Q...
    Medical condition: locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000542-20 Sponsor Protocol Number: UC-0103/1802 Start Date*: 2021-01-07
    Sponsor Name:UNICANCER
    Full Title: Randomized phase III study of oral cyclophosphamide vs doxorubicin in 65 years or older patients with advanced or metastatic soft tissue sarcoma: a UNICANCER/GERICO multicenter program
    Medical condition: Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004404-19 Sponsor Protocol Number: Acadmed18013 Start Date*: 2014-05-07
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pul...
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001383-28 Sponsor Protocol Number: M18-891 Start Date*: 2018-10-30
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate and Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) DK (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) DE (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002947-27 Sponsor Protocol Number: SIMCODE Start Date*: 2020-01-22
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial
    Medical condition: Patients with comorbid obesity (body mass index ≥ 30) and major depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002581-51 Sponsor Protocol Number: AK002-006 Start Date*: 2018-01-10
    Sponsor Name:Allakos Inc.
    Full Title: An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria
    Medical condition: Patients with different types of chronic urticaria resistant to standard dose antihistamines
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005443-14 Sponsor Protocol Number: NGAM-08 Start Date*: 2017-04-28
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: Prospective, double-blind, randomized, multicenter phase III study evaluating efficacy and safety of three different dosages of NewGam in patients with chronic inflammatory demyelinating poly(radic...
    Medical condition: Chronic Inflammatory Demyelinating Poly(radiculo)-neuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000666-10 Sponsor Protocol Number: m16-063 Start Date*: 2018-12-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subje...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005279-10 Sponsor Protocol Number: MT10109L-002 Start Date*: 2019-09-24
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
    Medical condition: Lateral Canthal Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002886-21 Sponsor Protocol Number: UC-0110/1809 Start Date*: 2018-12-11
    Sponsor Name:UNICANCER
    Full Title: A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma.
    Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000469-33 Sponsor Protocol Number: NL.76663.018.21 Start Date*: 2021-10-12
    Sponsor Name:Amsterdam UMC location AMC
    Full Title: A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in th...
    Medical condition: Crohns disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004307-30 Sponsor Protocol Number: IXA-CSP-001 Start Date*: 2017-03-30
    Sponsor Name:IXALTIS
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BI...
    Medical condition: Mixed Urinary Incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003383-47 Sponsor Protocol Number: TAK-079-1005 Start Date*: 2020-08-12
    Sponsor Name:MILLENNIUM PHARMACEUTICALS, INC.
    Full Title: A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005125-20 Sponsor Protocol Number: M16-045 Start Date*: 2018-09-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate and Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Trial now transitioned) FI (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001614-16 Sponsor Protocol Number: 16TETE04 Start Date*: 2016-09-22
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma.
    Medical condition: Recurrent glioblastoma.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001105-24 Sponsor Protocol Number: TALASUR Start Date*: 2020-12-21
    Sponsor Name:Centre François Baclesse
    Full Title: TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phase 2 trial
    Medical condition: Maintenance treatment in patients with locally advanced/metastatic urothelial carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 12:47:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA